`Declaration of Daralyn J. Durie
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`____________________________________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`____________________________________________
`
`CELLTRION, INC.,
`Petitioner,
`
`v.
`
`GENENTECH, INC.,
`Patent Owner.
`____________________________________________
`
`Case IPR2017-01374
`U.S. Patent 6,407,213
`____________________________________________
`
`
`
`DECLARATION OF DARALYN J. DURIE IN SUPPORT OF PATENT
`OWNER’S MOTION FOR PRO HAC VICE ADMISSION
`
`
`
`
`
`
`
`
`
`
`Celltrion v. Genentech
`IPR2017-01374
`Genentech Exhibit 2033
`
`
`
`I, Daralyn J. Durie, declare as follows:
`
`Case No. IPR2017-01374
`Declaration of Daralyn J. Durie
`
`
`1.
`
`2.
`
`I am an attorney licensed to practice law in the State of California.
`
`I am a partner at the law firm Durie Tangri LLP and have litigated
`
`cases relating to patents for the past seven years.
`
`3.
`
`I am a member in good standing of the State Bar of California and the
`
`United States Court of Appeal for the Federal Circuit. I am also admitted to
`
`practice before the United States Court of Appeals for the 1st Circuit, the United
`
`States Court of Appeals for the 3rd Circuit, the United States Court of Appeals for
`
`the 8th Circuit, the United States Court of Appeals for the 9th Circuit, the United
`
`States District Courts in the Northern, Central and Southern Districts of California.
`
`4.
`
`I am a member in good standing in all jurisdictions where I have been
`
`admitted to practice.
`
`5.
`
`I have never been suspended or disbarred from practice before any
`
`court or administrative body.
`
`6.
`
`I have never had an application denied for admission to practice
`
`before any court or administrative body.
`
`7.
`
`I have not had any sanctions or contempt citations imposed against me
`
`by any court or administrative body.
`
`8.
`
`I have read and will comply with the Office Patent Trial Practice
`
`Guide and the Board’s Rules of Practice for Trials set forth in part 42 of 37 C.F.R.
`
`
`
`2
`
`
`
`I agree to be subject to the USPTO Rules of Professional Conduct set
`
`Case No. IPR2017-01374
`Declaration of Daralyn J. Durie
`
`
`9.
`
`forth in 37 C.F.R. §§ 11.101 et seq., and disciplinary jurisdiction under 37 C.F.R. §
`
`11.19(a).
`
`10.
`
`In the last three (3) years, I have appeared Pro Hac Vice before the
`
`Patent Trial and Appeal Board in the following cases: Sanofi-Aventis U.S. LLC and
`
`Regeneron Pharmaceuticals, Inc. v. Genentech, Inc. and City of Hope, IPR2015-
`
`01624 (pro hac vice granted); Genzyme Corporation v. Genentech, Inc. and City of
`
`Hope, IPR2016-00460 (pro hac vice motion filed) (joined with IPR2015-01624);
`
`Genzyme Corporation v. Genentech, Inc. and City of Hope, IPR2016-00383 (pro
`
`hac vice motion filed) (not instituted); Merck Sharp & Dohme Corp. v. Genentech,
`
`Inc. and City of Hope, IPR2016-01373 (pro hac vice granted) (not instituted);
`
`Mylan Pharmaceuticals, Inc. v. Genentech, Inc. and City of Hope, IPR2016-00710
`
`(pro hac vice granted) (joined with IPR2017-00047) (terminated); Mylan
`
`Pharmaceuticals, Inc. v. Genentech, IPR2016-01693 (pro hac vice motion filed)
`
`(challenging U.S. Patent No. 6,407,213, that patent at issue in this case;
`
`terminated); Mylan Pharmaceuticals, Inc. v. Genentech, IPR2016-01694 (pro hac
`
`vice motion filed) (challenging U.S. Patent No. 6,407,213, that patent at issue in
`
`this case; terminated); Hospira, Inc.. v. Genentech, Inc., IPR2017-00731
`
`(institution denied July 27, 2017, request for rehearing filed August 25, 2017; pro
`
`hac vice granted October 2, 2017; instituted October 26, 2017, pending); Hospira,
`
`
`
`3
`
`
`
`Inc. v. Genentech, Inc., IPR2017-00737 (pro hac vice granted June 21, 2017,
`
`Case No. IPR2017-01374
`Declaration of Daralyn J. Durie
`
`
`pending); Hospira, Inc. v. Genentech, Inc., IPR2017-00739 (pro hac vice granted
`
`June 21, 2017; institution denied July 27, 2017); Hospira, Inc. v. Genentech, Inc.,
`
`IPR2017-00804 (pro hac vice granted October 2, 2017, pending); Hospira, Inc. v.
`
`Genentech, Inc., IPR2017-00805 (pro hac vice granted October 2, 2017, pending);
`
`Celltrion, Inc. v. Genentech, Inc., IPR2017-01121 (pro hac vice granted October
`
`30, 2017, pending); Celltrion, Inc. v. Genentech, Inc., IPR2017-01122 (pro hac
`
`vice granted October 30, 2017, pending); Celltrion, Inc. v. Genentech, Inc.,
`
`IPR2017-01139 (pro hac vice granted October 30, 2017, pending); Celltrion, Inc.
`
`v. Genentech, Inc., IPR2017-01140 (pro hac vice granted October 30, 2017,
`
`pending); Celltrion, Inc. v. Genentech, Inc., IPR2017-01373 (pro hac vice motion
`
`to be filed, pending); Pfizer, Inc. v. Genentech, Inc., IPR2017-01488 (pro hac vice
`
`granted September 27, 2017, pending); Pfizer, Inc. v. Genentech, Inc., IPR2017-
`
`01489 (pro hac vice granted September 27, 2017, pending); Pfizer, Inc. v.
`
`Genentech, Inc., IPR2017-01726 (pro hac vice motion to be filed, pending); Pfizer,
`
`Inc. v. Genentech, Inc., IPR2017-01727 (pro hac vice motion to be filed, pending);
`
`Samsung Bioepis, Co. Ltd. v. Genentech, Inc., IPR2017-01958 (pro hac vice
`
`motion to be filed, pending); Samsung Bioepis, Co. Ltd. v. Genentech, Inc.,
`
`IPR2017-01959 (pro hac vice motion to be filed, pending); Samsung Bioepis, Co.
`
`Ltd. v. Genentech, Inc., IPR2017-01960 (joined to IPR2017-00737); Pfizer, Inc. v.
`
`
`
`4
`
`
`
`Genentech, Inc., IPR2017-02019 (pro hac vice to be filed, pending); Pfizer, Inc. v.
`
`Case No. IPR2017-01374
`Declaration of Daralyn J. Durie
`
`
`Genentech, Inc., IPR2017-02020 (pro hac vice to be filed, pending); Boehringer
`
`Ingelheim Pharmaceuticals, Inc. v. Genentech, Inc., IPR2017-02031 (pro hac vice
`
`to be filed, pending); Boehringer Ingelheim Pharmaceuticals, Inc. v. Genentech,
`
`Inc., IPR2017-02032 (pro hac vice to be filed, pending); Pfizer, Inc. v. Genentech,
`
`Inc., IPR2017-02063 (pro hac vice to be filed, pending); Samsung Bioepis, Co.
`
`Ltd. v. Genentech, Inc., IPR2017-02139 (pro hac vice to be filed, pending);
`
`Samsung Bioepis, Co. Ltd. v. Genentech, Inc., IPR2017-02140 (pro hac vice to be
`
`filed, pending); Pfizer, Inc. v. Genentech, Inc., IPR2018-00016 (pro hac vice to be
`
`filed, pending); Samsung Bioepis, Co. Ltd. v. Genentech, Inc., IPR2018-00192 (pro
`
`hac vice to be filed, pending).
`
`11.
`
`I have been litigating patent cases for 23 years. I have an established
`
`familiarity with the subject matter at issue in this proceeding. I have handled
`
`patent cases relating to recombinant antibodies for more than 16 years, and have
`
`represented Genentech in many of these patent cases. I have worked closely with
`
`Adam R. Brausa, counsel for Patent Owner in this matter.
`
`12. Additionally, I am familiar with the matters involved in and
`
`implicated by these proceedings, including the ’213 patent and its file history, the
`
`prior art presented in the petition, and the legal and factual issues raised by
`
`Petitioner in this proceeding. As a result, I have acquired substantial
`
`
`
`5
`
`
`
`understanding of the underlying legal and technological issues at stake in this
`
`Case No. IPR2017-01374
`Declaration of Daralyn J. Durie
`
`
`proceeding.
`
`I hereby declare that all statements made herein of my own knowledge are
`
`true and that all statements made on information and belief are believed to be true;
`
`and further that these statements are made with the knowledge that willful false
`
`statements and the like so made are punishable by fine or imprisonment, or both,
`
`under Section 1001 of Title 18 of the United States Code.
`
`Date: January 10, 2018
`
`
`
`
`
`
`
`
`
`Daralyn J. Durie
`
`Durie Tangri LLP
`217 Leidesdorff Street
`San Francisco, CA 94111
`
`6
`
`